Premium
Blood monocyte aryl hydrocarbon hydroxylase activity in psoriasis.
Author(s) -
Mason G,
Rawlins MD,
Shuster S
Publication year - 1983
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1983.tb02170.x
Subject(s) - psoriasis , monocyte , basal (medicine) , chemistry , significant difference , aryl hydrocarbon receptor , polycyclic aromatic hydrocarbon , medicine , hydrocarbon , endocrinology , pharmacology , immunology , biochemistry , organic chemistry , transcription factor , insulin , gene
The activity of aryl hydrocarbon hydroxylase (AHH) in monocytes from 13 healthy control subjects and in 16 patients with discoid psoriasis was measured. The mean basal monocyte AHH activities of the control and psoriatic groups were 3.4 +/‐ 0.47 and 4.46 +/‐ 0.55 respectively (pmol 3‐OHBP h‐1 10(‐6) cells). This difference was not significant. The mean induced monocyte AHH activities in the control and psoriatic groups were 56.4 +/‐ 10.8 and 77.8 +/‐ 16.0 pmol 3‐OHBP h‐1 10(‐6) cells respectively but this difference was not significant. The mean induction ratios in the control and psoriatic groups were 16.5 +/‐ 1.8 and 20.4 +/‐ 3.6 respectively. Again, this difference was not significant. We conclude therefore, that monocyte aryl hydrocarbon hydroxylase activity is not reduced in psoriasis.